Compare GE Aerospace (GE) vs Novo Nordisk A/S (NVO) Price & Performance

GE AerospaceTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

GE Aerospace vs Novo Nordisk A/S — how do they compare? GE Aerospace trades at $347.3 (market cap $375.97B), while Novo Nordisk A/S trades at $51.45 (market cap $222.24B). The key difference: GE Aerospace is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.56%). Which is the better fit depends on your goals.

	GE	NVO
Market Cap	$375.97B	$222.24B
Sector	Industrials	Health
52-Week High	$378.68	$71.70
52-Week Low	$259.00	$35.29
Enterprise Value	$385.26B	$241.20B
Dividend Yield	0.52%	3.56%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GE Aerospace

GE trades at $353.73, up 0.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q1 2026 EPS of $1.86 versus $1.60 expected, driven by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margin improving to 18.98%. Analysts maintain a strong buy consensus with a $402.63 price target, reflecting optimism about order growth and backlog strength.

Outlook remains positive given earnings momentum and strategic investments in MRO and propulsion, though high valuation ratios (P/E 43.94) and debt levels pose risks. The stock offers upside to consensus targets but faces pressure from rising costs and competitive dynamics in aerospace and defense sectors.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.

The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GE Aerospace expects strong Q2 2026 with EPS $1.86 and 16.8% revenue growth, stock target raised to $400.Rayan Ahmad · 17 hours agoBullish Mar Vista's U.S. Quality strategy gains 12.71% in Q2 2026, lagging broader market indexes.Seeking Alpha · 2 days agoBullish GE Aerospace stock rises nearly 17% YTD but lags behind broader industrial ETF's 18% gain.24/7 Wall Street · 3 days agoBullish View details →

NVO

European Commission approves Wegovy, first oral GLP-1 weight loss pill in EU by Novo Nordisk.Benzinga · 23 hours agoBullish Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trendsCustom Market Insights · 2 days agoBullish View details →

About GE Aerospace

General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.